目的研究美沙拉嗪和柳氮磺吡啶口服对溃疡性结肠炎患者肠黏膜中TLR4和NF-κb表达量的影响。方法将该院接受美沙拉嗪治疗的80例慢性溃疡性结肠炎患者纳入研究的观察组,同期接受柳氮磺砒啶治疗的80例慢性溃疡性结肠炎患者纳入对照组。比...目的研究美沙拉嗪和柳氮磺吡啶口服对溃疡性结肠炎患者肠黏膜中TLR4和NF-κb表达量的影响。方法将该院接受美沙拉嗪治疗的80例慢性溃疡性结肠炎患者纳入研究的观察组,同期接受柳氮磺砒啶治疗的80例慢性溃疡性结肠炎患者纳入对照组。比较两组患者的临床症状和肠道黏膜评分,采用荧光定量PCR的方法检测肠道黏膜中TLR4和NF-κb的m RNA含量。结果观察组患者的腹痛、腹泻、脓血便以及黏膜评分均低于对照组。治疗后,两组患者肠道黏膜中TLR-4和NF-κb m RNA含量均低于治疗前;且治疗后观察组患者肠道黏膜中TLR-4 m RNA含量和NF-κb m RNA含量均低于对照组(P<0.05)。肠道黏膜中TLR-4和NF-κb的m RNA含量与腹痛、腹泻、脓血便和黏膜评分呈正相关(P<0.05)。结论美沙拉嗪能够更为有效的改善临床症状和黏膜情况,其作用可能是通过抑制肠道黏膜中TLR4和NF-κb的表达来发挥的。展开更多
INTRODUCTIONThe 1990’s have brought a significant promise and the hopefor a better and brighter future in the new millennium forpatients with inflammatory bowel disease(IBD).A betterunderstanding of the pathophysiolo...INTRODUCTIONThe 1990’s have brought a significant promise and the hopefor a better and brighter future in the new millennium forpatients with inflammatory bowel disease(IBD).A betterunderstanding of the pathophysiology of IBD symptoms hasled to newer treatment modalities and streamlining oftherapy for specific subsets of patients.展开更多
文摘目的研究美沙拉嗪和柳氮磺吡啶口服对溃疡性结肠炎患者肠黏膜中TLR4和NF-κb表达量的影响。方法将该院接受美沙拉嗪治疗的80例慢性溃疡性结肠炎患者纳入研究的观察组,同期接受柳氮磺砒啶治疗的80例慢性溃疡性结肠炎患者纳入对照组。比较两组患者的临床症状和肠道黏膜评分,采用荧光定量PCR的方法检测肠道黏膜中TLR4和NF-κb的m RNA含量。结果观察组患者的腹痛、腹泻、脓血便以及黏膜评分均低于对照组。治疗后,两组患者肠道黏膜中TLR-4和NF-κb m RNA含量均低于治疗前;且治疗后观察组患者肠道黏膜中TLR-4 m RNA含量和NF-κb m RNA含量均低于对照组(P<0.05)。肠道黏膜中TLR-4和NF-κb的m RNA含量与腹痛、腹泻、脓血便和黏膜评分呈正相关(P<0.05)。结论美沙拉嗪能够更为有效的改善临床症状和黏膜情况,其作用可能是通过抑制肠道黏膜中TLR4和NF-κb的表达来发挥的。
文摘INTRODUCTIONThe 1990’s have brought a significant promise and the hopefor a better and brighter future in the new millennium forpatients with inflammatory bowel disease(IBD).A betterunderstanding of the pathophysiology of IBD symptoms hasled to newer treatment modalities and streamlining oftherapy for specific subsets of patients.
